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The myogenic regulatory factors MyoD and myogenin are crucial for skeletal muscle development. Despite their importance, the mechanisms
by which these factors selectively regulate different target genes are unclear. The purpose of the present investigation was to compare embryonic
skeletal muscle from myogenin+/+ and myogenin−/− mice to identify genes whose expression was dependent on the presence of myogenin but not
MyoD and to determine whether myogenin-binding sites could be found within regulatory regions of myogenin-dependent genes independent of
MyoD. We identified a set of 140 muscle-expressed genes whose expression in embryonic tongue muscle of myogenin−/− mice was
downregulated in the absence of myogenin, but in the presence of MyoD. Myogenin bound within conserved regulatory regions of several of the
downregulated genes, but MyoD bound only to a subset of these same regions, suggesting that many downregulated genes were selective targets
of myogenin. The regulatory regions activated gene expression in cultured myoblasts and fibroblasts overexpressing myogenin or MyoD,
indicating that expression from exogenously introduced DNA could not recapitulate the selectivity for myogenin observed in vivo. The results
identify new target genes for myogenin and show that myogenin's target gene selectivity is not based solely on binding site sequences.
© 2007 Elsevier Inc. All rights reserved.Keywords: Skeletal muscle development; bHLH myogenic regulatory factors; Myogenin; MyoD; Target gene selection; Gene expression profiling; Chromatin
immunoprecipitationIntroduction
As transcription factor families evolve, individual members
adopt specialized functions for selectively regulating gene
expression. Specialization within transcription factor families
is considered to be an important driver of developmental di-
versity (Kirschner and Gerhart, 1998) but how closely related
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doi:10.1016/j.ydbio.2007.08.014remains poorly understood. Vertebrate skeletal muscle develop-
ment is a well-established model for investigating the mecha-
nisms by which related transcription factors selectively regulate
the expression of distinct sets of genes (Olson and Klein, 1994;
Black and Olson, 1998; Buckingham et al., 2003). In all
vertebrates studied to date, two transcription factor families are
essential for activating the gene regulatory network that drives
skeletal muscle development during embryogenesis— the four
closely related myogenic basic helix–loop–helix (bHLH)
regulatory factors, MyoD, Myf5, myogenin, and MRF4/Myf6,
and the multiple isoforms of the MADS-box factors, Mef2a,
Mef2c, and Mef2d (Blais et al., 2005). For full activity, the
myogenic bHLH regulatory factors dimerize with E proteins to
bind conserved E-box sequences in the regulatory regions of
muscle genes (Berkes and Tapscott, 2005).
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particularly relevant to our study. Although these transcription
factors have virtually identical bHLH regions and extensive
similarity in the remainder of their sequences, they nevertheless
play very different roles in myogenesis (Bergstrom and
Tapscott, 2001; De la Serna et al., 2005; Berkes and Tapscott,
2005). Specifically, MyoD functions early in myogenesis to
confer a myogenic fate on mesodermal progenitor cells,
whereas myogenin functions later to cause specified myoblasts
to differentiate into functional myofibers (Buckingham et al.,
2003; Berkes and Tapscott, 2005).
Recent studies using cultured myoblasts or fibroblasts have
revealed functional distinctions between MyoD and myogenin
at the molecular level (Berkes and Tapscott, 2005; De la Serna
et al., 2005; Tapscott, 2005). MyoD has specialized domains
that are involved in chromatin remodeling but myogenin does
not have these domains (Bergstrom and Tapscott, 2001; Cao et
al., 2006; Ohkawa et al., 2006). Thus, MyoD binds to regulatory
regions of skeletal muscle genes, promotes nucleosome
remodeling, and recruits transcriptional co-activators (Berkes
and Tapscott, 2005; De la Serna et al., 2005; Tapscott, 2005).
Furthermore, MyoD binds to regulatory regions of genes
expressed early in myogenesis and activates their expression
(Cao et al., 2006; Ohkawa et al., 2006, 2007). MyoD also binds
to regulatory regions of genes expressed later in myogenesis
and initiates nucleosome remodeling but is thought to be
insufficient for gene activation (De la Serna et al., 2005; Cao et
al., 2006). In contrast, myogenin does not appear to bind to gene
regulatory regions early in myogenesis but is thought to bind
efficiently within the regulatory regions of genes expressed late
in myogenesis following chromatin remodeling by MyoD.
Genes activated late in myogenesis may require both MyoD and
myogenin binding within the regulatory region (Cao et al.,
2006) or require that MyoD remodels chromatin before
myogenin can be recruited for binding (De la Serna et al.,
2005; Cao et al., 2006; Ohkawa et al., 2006, 2007).
Despite recent progress, many key issues remain unresolved.
During embryonic muscle development in vivo, many skeletal
muscle genes are not readily classified as early- or late-expressed
genes. Whether all late-expressing genes require simultaneous
binding of MyoD and myogenin at sites within regulatory
regions to activate gene expression is unclear. Additionally, most
of the studies attempting to distinguish the differences between
MyoD and myogenin have been carried out with C2C12
myoblasts or other tissue culture cells. To be meaningful, the
results require validation in vivo.
Myogenin stands out among the myogenic regulatory factors
in one important aspect: unlike the phenotypes observed with
single knockouts of the three other myogenic regulatory genes,
a strong skeletal muscle phenotype is associated with a single
knockout of myogenin (myog) in mice (Olson and Klein, 1994;
Buckingham, 2001). Mice homozygous for a myog-null allele
die at birth because of severe skeletal muscle deficiency (Hasty
et al., 1993; Nabeshima et al., 1993). In late-stage embryos,
myog−/− myoblasts are specified for a muscle fate throughout
the body but myofiber formation is impaired. Despite this strong
phenotype, several muscle-specific genes are expressed inmyog−/− mice indicating that not all genes involved in muscle
differentiation are controlled by myogenin (Venuti et al., 1995).
Notably,myoD expression is not affected by a loss of myogenin,
demonstrating that MyoD cannot compensate for myogenin's
absence in vivo (Rawls et al., 1995; Venuti et al., 1995). In
addition, myog−/− embryonic stem (ES) cells, when induced to
differentiate, form far fewer myotubes than wild-type ES cells
do, and forced overexpression of myoD in myog−/− ES cells
does not make up for myotube deficiencies (Myer et al., 2001).
MyoD and myogenin thus differ fundamentally. Because
MyoD and myogenin are DNA-binding proteins and transcrip-
tional activators, the functional differences between them must
be accounted for in regulating the expression of distinct gene
sets during myogenesis. The question then arises whether any
genes targeted by myogenin can be identified that are not also
targets of MyoD. The purpose of the present investigation was
to compare embryonic skeletal muscle from myog+/+ and
myog−/− mice to identify genes whose expression was
dependent on the presence of myogenin but not MyoD and to
determine whether myogenin-binding sites can be found within
the regulatory regions of myogenin-dependent genes indepen-
dent of MyoD.
Using a microarray platform, we performed gene expression
profiling to identify a set of genes whose expression was
significantly downregulated in the embryonic tongue muscle of
myog−/− mice in the absence of myogenin. We identified
putative phylogenetically conserved transcriptional regulatory
regions associated with several myogenin-dependent genes and
found enhancer E-box elements within these regulatory regions
that were bound by myogenin but not MyoD. The transcrip-
tional activity of these regulatory regions in cultured myoblasts
and fibroblasts suggested that the ability to discriminate
between myogenin and MyoD in activating gene transcription
requires more than target sequence specificity.
Materials and methods
Affymetrix microarray analysis
Myog+/− mice were intercrossed, and tongue tissue samples from the
resulting embryos were harvested at embryonic day 15.5 (E15.5) and stored in
RNAlater (Ambion). In all experiments using myog+/+, myog+/−, and myog−/−
mice, the U.S. Public Health Service Policy on Humane Care and Use of
Laboratory Animals was followed and the M. D. Anderson Institutional Animal
Care and Use Committee approved all animal protocols for these experiments.
Myog+/− mice were maintained on a C57/BL/6J background. Total RNA was
extracted from the samples using an RNeasy fibrous tissue kit (Qiagen). Five
micrograms of total RNA from each sample was used for preparing
hybridization probes. Three independent samples were used in standard
Affymetrix protocols to yield fluorescently labeled cRNA fragments, which
were hybridized to Mouse Genome 430 2.0 GeneChips (Affymetrix). The
hybridized GeneChips were scanned using an Affymetrix GeneArray scanner,
and the raw image files were analyzed using ArrayAssist 4.0 (Stratagene) with
PLIER (Probe Logarithmic Intensity Error) normalization (Katz et al., 2006).
P-values were calculated using unpaired t-tests between myog+/+ and
myog−/− datasets. Genes were grouped based on their reported Gene Ontology
Biological Process descriptions (Hill et al., 2002). All annotations are as
reported by the NetAffx Analysis Center (http://www.affymetrix.com/analysis/
index.affx). We also used the gene descriptors available at the National Center
for Biotechnology (NCBI) Information Mouse Genome Resource web site
(http://www.ncbi.nlm.nih.gov/genome/guide/mouse/) to assist in grouping the
652 J.K. Davie et al. / Developmental Biology 311 (2007) 650–664genes. The complete microarray dataset is listed in Table S1 and the subset that
includes the downregulated genes is listed in Table S2.
Quantitative reverse-transcriptase polymerase chain reaction
Two micrograms of total RNA from E15.5 embryonic tongue tissue of
myog+/+ or myog−/− mice was reversed transcribed with Superscript reverse-
transcriptase (Invitrogen). cDNA equivalent to 40 ng was used for quantitative
polymerase chain reaction (qPCR) amplification (Applied Biosystems) with
SYBR green PCR master mix (Applied Biosystems). The relative levels of
expression of genes selected from the microarray analysis were normalized
according to those of ribosomal protein L7 (Rpl7). qPCR data were calculated
using the comparative Ct method (Applied Biosystems). Standard deviations
from the mean of the [Δ]Ct values were calculated from three independent RNA
samples. The PCR primers used for detecting the transcripts of the selected
genes are listed in Table S3.
In situ hybridization and immunocytochemistry
Twelve-micrometer frozen sections were obtained from 4% paraformalde-
hyde-fixed tongue and heart samples dissected from E15.5myog+/+ andmyog−/−
embryos. To generate antisense and sense probes for in situ hybridization, PCR
products from cDNAs derived from tongue tissue samples were cloned into the
vector pCRII-TOPO (Invitrogen). The cloned products were linearized using
either HindIII or XbaI and subsequently transcribed in vitro using T7 RNA
polymerase for the antisense probe and Sp6 RNA polymerase for the sense
probe in the presence of digoxigenin (Boehringer-Mannheim, Germany). Non-
radioactive in situ hybridization was performed to detect spatial expression as
previously described (Lee et al., 2000). Nuclear Fast Red was used for
counterstaining of the tissue samples. For double in situ hybridization
immunocytochemistry, sections of E15.5 myog+/+ and myog−/− tongue tissue
were washed in phosphate-buffered saline (PBS, pH 7.2–7.4) and immunocy-
tochemistry was carried out as described below.
For immunocytochemistry, endogenous peroxidase activity and nonspecific
antibody binding in sectioned tissues were blocked using 3% hydrogen peroxide
and 3% bovine serum albumin (BSA) in PBS for 1 h. Rabbit anti-MyoD
(M-318) and anti-myogenin (M-225) antibodies (Santa Cruz Biotechnology)
were used at dilutions of 1:200 and 1:800, respectively. Antibodies were diluted
in 3% normal goat serum in PBS containing 3% bovine serum albumin, and
sections of tongue tissue were incubated with the antibodies at 4 °C for 16 h.
Immunoreactivity in the sections was visualized using an ABC kit (Vector
Laboratories) for colorimetric visualization. Methyl green was used for
counterstaining of the sectioned tissues in both immunocytochemistry and
double in situ hybridization immunocytochemistry labeling experiments.
Chromatin Immunoprecipitation analysis of embryonic tissue
E15.5 tongue tissue from myog+/+ mice was isolated, cross-linked, and
processed for chromatin immunoprecipitation (ChIP) analysis as previously
described (Wells and Farnham, 2002). Extracts of tongue tissue were precleared
using incubation with preblocked protein-A agarose beads (Upstate Biotechnol-
ogies), which were also used to immunoprecipitate the antibody complexes from
tongue tissue extracts following antibody addition to the incubation mix. The
antibodies used in the ChIP analysis were a ChIP-grade anti-MyoD antibody
(C-20; Santa Cruz Biotechnology) and a ChIP-grade anti-myogenin antibody
(M-225; Santa Cruz Biotechnology). Twomicrograms of the antibodies was used
for each immunoprecipitation and with extracts corresponding to approximately
1.5 tongues for each immunoprecipitation. The antibodies showed no cross-
reactivity as determined using immunoprecipitation with one antibody followed
by Western blot analysis with the second antibody (data not shown). The PCR
primers used for detecting protein-bound DNA in embryonic tongue extracts are
listed in Table S3. DNAwas amplified by qPCR using SYBR green PCR master
mix (Applied Biosystems). The data are presented as the fold change between
samples with and without antibodies with each sample normalized according to
Rpl7. Input samples were tested for amplification and to compare samples across
replicates but were not used for normalization. Inputs for all samples were
identical, as extracts were obtained from pooled tongue tissue samples andaliquoted for immunoprecipitation. qPCR data were calculated using the com-
parative Ct method. Values of [Δ][Δ]Ct were determined by applying the
following formula: [Δ]Ct,template (experimental)− [Δ]Ct,reference (Rpl7)= [Δ][Δ]
Ct. Fold enrichments were calculated as 2
−[Δ][Δ]Ct (antibody) /2−[Δ][Δ]Ct (no
antibody). Standard error from the mean was calculated from replicate [Δ][Δ]Ct
values.
Transient transfection and luciferase assays
Upstream gene regulatory regions were amplified from genomic DNA using
PCR and cloned into the pGL3 luciferase reporter gene vector (Invitrogen). The
regulatory regions of candidate myogenin target genes used were AMP dea-
minase 1 (Ampd1; base pairs −8 to −431), LIM domain binding protein 3 (Ldb3;
base pairs −1 to −1209), Leiomodin2 (Lmod2; base pairs −10 to −458), and
Calsequestrin2 (Casq2; base pairs −3 to −760). Base pair positions are defined
with respect to the translational A(TG) start site with A considered to be +1.
Fugene 6 and Fugene HD transfection reagents (Roche) were used for DNA
transfections and the level of luciferase activity in transfected cells was
determined using a dual-luciferase reporter assay system (Promega). The
plasmids EMSVmyog (provided by Diane Edmondson, Tanex, Inc.) and
pEMCIIs (provided by Andrew Lassar, Harvard Medical School) were used
for expressing myog and myoD, respectively, in transfected NIH-3T3 cells.
C2C12 and NIH-3T3 cells were grown in Dulbecco's modified Eagle's medium
containing 10% bovine calf serum, 2% L-glutamine, 1% penicillin–streptomycin
according to standard tissue culture protocols (Pollard andWalker, 1997). C2C12
cells were induced to differentiate into myotubes by allowing the cells to reach
confluence and switching the medium to Dulbecco's modified Eagle's medium
in 2%horse serum, 0.2% L-glutamine, 0.5% penicillin–streptomycin. Expression
values for each construct were calculated as a percentage of expression of the
pGL3 control vector. Standard deviations from the mean was calculated from the
mean expression values representing at least three separate experiments.
The math5 expression construct was generated by cloning the complete
math5 coding sequence (Mu et al., 2005) into the pIRES-hrGFP-1a vector in
frame with 3× FLAG sequences. Transactivation experiments were performed at
least in duplicate using NIH-3T3 cells and Fugene HD transfection reagent. E-
boxes identified as putative myogenin-binding sites through ChIP analysis were
deleted from the Lmod2 and Ampd1 vectors using the QuickChange II site-
directed mutagenesis kit (Stratagene). Primer sequences used to generate the
mutations are listed in Table S3. Transactivation experiments were performed at
least in duplicate using NIH-3T3 cells and Fugene HD transfection reagent.Results
Identification of myogenin-dependent genes in E15.5 tongue
muscle
From E12.5 to E18.5, committed myoblasts throughout the
muscle-forming regions of the body differentiate into myocytes
and fuse to form myofibers (Venuti et al., 1995). Myog
expression begins at E8.5 in the dermamyotome and continues
thereafter at all sites of skeletal muscle development (Cheng et
al., 1992; Venuti et al., 1995). We elected to perform gene
expression profiling at E15.5 with embryonic tongue muscle.
Myog+/+ andmyog−/− tongues look very much alike at that time,
although severe deficiencies in myofibers in myog−/− embryo-
nic tongues become apparent later.
We extracted RNA from tongue tissue samples from three
independent myog+/+ and myog−/− embryos and used them to
generate biotin-labeled cRNA probes for hybridization to
Mouse Genome 430 2.0 GeneChips. We used ArrayAssist 4.0
to analyze the microarray hybridization results and used PLIER
normalization to identify selected genes that showed changes in
expression with P values≤0.05 and empirically chosen fold
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was downregulated and 240 genes whose expression was
upregulated that met these criteria.
Myogenin functions mainly as a transcriptional activator al-
though, in certain cases, it may act to repress transcription
(Trouche et al., 1995). However, because our objective was to
identify direct target genes whose expression was activated by
the presence of myogenin, we focused on the downregulatedTable 1
Fifty representative genes whose expression is downregulated in E15.5 tongue mus
Gene title Gen
RIKEN cDNA 1100001E04 gene 1100
Leiomodin 2 (cardiac) Lmo
Troponin T3, skeletal, fast Tnnt
Myogenin Myo
Cysteine and glycine-rich protein 3 Csrp
Cytochrome c oxidase muscle isoform 8b Cox8
Creatine kinase, mitochondrial 2 Ckm
Troponin I-2 Tnni
Integrin beta 1 binding protein 2 Itgb1
Myogenic factor 6 Myf6
Spastic paraplegia 21 homologue (human) Spg2
Myosin, light polypeptide 3 Myl3
Myozenin 2 Myo
Myozenin 1 Myo
Dystrophia myotonica-protein kinase Dmp
Myosin heavy chain 1 Myh
Adenylosuccinate synthetase like 1 Adss
Tubulin, beta 6 Tubb
Myosin, light polypeptide 1 Myl1
Myomesin 2 Myo
Interleukin 17B Il17b
Calsequestrin 2 Casq
Interferon gamma induced GTPase Igtp
Cytochrome c oxidase, subunit 6a, polypeptide 2 Cox6
Serine/Threonine kinase 23 Stk2
Nephroblastoma overexpressed gene Nov
Myosin, light polypeptide 2, regulatory, cardiac, slow Myl2
LIM domain protein binding 3 Ldb3
Small muscle protein, X-linked Smp
Double cortin and calcium/calmodulin-dependent protein kinase-like 1 Dca
Zyxin Zyx
Upregulated during skeletal muscle growth 4 Usm
Sarcalumenin Srl
Transcription elongation factor A (SII), 3 Tcea
PDZ and LIM domain 5 Pdli
Titin Ttn
Enabled homologue (Drosophila) Enah
CDC42 effector protein (Rho GTPase binding) 2 Cdc4
Translin-associated factor X Tsna
Synaptic nuclear envelope 1 Syne
Fibroblast growth factor receptor-like 1 Fgfr
Calcium channel, voltage-dependent, alpha2/delta subunit 1 Cacn
AMP deaminase 1 (isoform M) Amp
Tropomodulin 4 Tmo
Titin-cap Tcap
Junctophilin 2 Jph2
Fibroblast growth factor 6 Fgf6
Cofilin 2, muscle Cfl2
Actin binding LIM protein family, member 3 Abli
Actinin α2 Actn
Fold change calculations for the Affymetrix array and qRT-PCR analyses are desc
although the fold change in the expression of this gene calculated using the array anal
values calculated using qRT-PCR.genes. The complete set of upregulated and downregulated genes
are listed in Table S1, but in contrast to the downregulated genes
(see below), we failed to validate a sampling of the upregulated
genes by independent qRT-PCR analysis (data not shown). This
suggests that many of the upregulated genes identified by the
microarray analysis were not bona fide targets of myogenin.
Of the 140 downregulated genes, 117 were previously
characterized, while 23 were identified as genes encodingcle samples obtained from myog−/− embryos fold changes (myog+/+/myog−/−)
e symbol Probe set ID Array qRT-PCR SD
001E04Rik 1454660_at 5.7 12.4 3.4
d2 1452345_at 4.2 18.3 4.2
3 1450118_a_at 4.1 – –
g 1419391_at 3.7 – –
3 1460318_at 3.7 8.3 2.8
b 1449218_at 3.3 8.7 1.1
t2 1428722_at 3.3 2.8 0.2
2 1438609_x_at 3.2 6.1 1.1
bp2 1423238_at 3.1 6.1 0.9
1419150_at 3.0 8.2 0.3
1 1451036_at 2.7 – –
1427768_s_at 2.7 – –
z2 1418769_at 2.6 6.9 0.9
z1 1460202_at 2.6 14.4 3.4
k 1434944_at 2.6 – –
1 1427868_x_at 2.5 4.5 0.7
l1 1449383_at 2.5 4.7 0.7
6 1416431_at 2.4 – –
1452651_a_at 2.4 – –
m2 1450917_at 2.4 3.6 0.1
1431693_a_at 2.4 – –
2 1422529_s_at 2.4 3.9 0.4
1417141_at 2.3 – –
a2 1417607_at 2.3 6.4 0.3
3 1447806_s_at 2.2 5.1 0.6
1426852_x_at 2.2 4.2 1.0
1448394_at 2.2 – –
1416752_at 2.2 8.2 2.2
x 1418095_at 2.1 3.8 1.0
mkl1 1436659_at 2.1 4.2 0.7
1417240_at 2.0 2.7 0.1
g4 1417626_at 2.0 – –
1436867_at 2.0 – –
3 1424531_a_at 1.9 4.9 0.8
m5 1429783_at 1.8 – –
1431928_at 1.7 – –
1421624_a_at 1.7 1.5 0.3
2ep2 1428750_at 1.7 3.3 0.9
x 1430045_at 1.6 – –
1 1455493_at 1.6 – –
l1 1447878_s_at 1.6 7.7 4.4
a2d1 1433643_at 1.6 – –
d1 1434722_at 1.6 30.5 9.3
d4 1449969_at 1.5 – –
1423145_a_at 1.5 – –
1455404_at 1.5 – –
1427582_at 1.5 6.0 2.7
1418067_at 1.5 – –
m3 1434013_at 1.5 – –
2 1456968_at 1.2 3.2 0.5
ribed in Materials and methods. One gene, Actn2, was included in the dataset
ysis was less than 1.5. SD, standard deviation from the mean for the fold-change
Table 2
Expression of MRFs in E15.5 tongue muscle samples obtained from myog−/−
embryos Fold changes (myog−/−/myog+/+)
MRF Affymetrix microarray qRT-PCR mean±SD
myoD 1.37 1.25±0.12
myf5 0.90 0.83±0.09
mrf4 (myf6) 0.33 0.12±0.07
The fold changes in MRF expression for the Affymetrix microarray and qRT-
PCR analyses were calculated as described in Materials and methods. For qRT-
PCR, the values were normalized relative to Rpl7 expression. SD, mean
standard deviation.
654 J.K. Davie et al. / Developmental Biology 311 (2007) 650–664hypothetical proteins by gene prediction algorithms. Virtually
all of the 117 known downregulated genes were represented in
various skeletal muscle EST databases and many encoded
structural or enzymatic components of skeletal muscle (Table
S2). Table 1 presents fifty selected genes that were all down-
regulated in myog−/− tongue muscle. Examples included
myosin heavy chain 1 (Myh1), Leiomodin2 (Lmod2), Troponin
I-2 (Tnni2), Titin (Ttn), Actinin α2 (Actn2), cytochrome c
oxidase muscle isoform 8b (Cox8b), muscle-specific serine/
threonine kinase 23 (Stk23), Calsequestrin2 (Casq2), and AMP
deaminase1 (Ampd1).
Genes encoding subunits of the sarcomeric Z-disks were
strongly represented in the downregulated set. These genes
included Myozenin1 (Myoz1), Myozenin2 (Myoz2), muscle-
specific integrin β1 binding protein2 (Itgβ1bp2), and LIM
domain binding protein3 (Ldb3). This finding was particularly
notable because Z-disks in residual myofibers within myog−/−
muscle are either severely disrupted or completely absent
(Nabeshima et al., 1993). The gene expression profiling results
provided a molecular explanation for this phenotype andFig. 1. Myogenin protein expression is absent from E15.5 tongue muscle obtained fro
expression detected using immunostaining with M-225, an anti-myogenin antibody. (
anti-MyoD antibody.suggested that myogenin plays a selective role in controlling
the expression of Z-disk components.
The microarray analysis also identified Fibroblast growth
factor 6 (Fgf6) and Fibroblast growth factor receptor-like 1
(Fgfrl1) as significantly downregulated genes. FGF6 is known
to regulate myogenesis (Armand et al., 2006) and FGFRL1 is
expressed in skeletal muscle and is thought to act as a decoy
receptor for fibroblast growth factor ligands (Trueb et al., 2003).
Myogenic regulatory factor expression in myog−/− embryonic
tongue muscle
Our gene profiling analysis included all the myogenic
regulatory factors (Table 2). Previous reports showed that the
expression of myoD and myf5 was not altered in myog−/−
embryos (Rawls et al., 1995; Venuti et al., 1995). These genes
are genetically upstream of myog and have roles in myoblast
specification. We confirmed that myoD and myf5 were
expressed at wild-type levels in myog−/− tongues in our
microarray experiments and qRT-PCR analysis (Table 2). In
contrast with the expression myoD and myf5, expression of
mrf4 (myf6) was strongly downregulated in myog−/− embryonic
tongues as had been reported previously in embryonic limb
muscle (Table 2; Rawls et al., 1995).
Immunostaining of embryonic tongue tissue with anti-
myogenin and anti-MyoD antibodies vividly illustrates the
independence of MyoD protein expression from myogenin
(Fig. 1). In myog+/+ tongues, we detected expression of both
myogenin (Fig. 1A) and MyoD (Fig. 1C) in well-organized
myofibers oriented longitudinally. In myog−/− tongues, we
could not detect myogenin expression above nonspecific
background staining (Fig. 1B) whereas we observed high levelsm myog−/− embryos but MyoD protein expression is unaltered. (A, B) Myogenin
C, D) MyoD protein expression detected using immunostaining with M-318, an
655J.K. Davie et al. / Developmental Biology 311 (2007) 650–664of MyoD expression in unfused myocytes (Fig. 1D). These
results confirmed previous findings (Hasty et al., 1993; Venuti
et al., 1995) and further demonstrated that the presence of
MyoD is insufficient for myofiber formation in the absence of
myogenin.
Functional and expression properties of putative myogenin
target genes
To validate our microarray results, we examined the
expression of 27 downregulated genes using qRT-PCR. We
extracted RNA from E15.5 myog+/+ and myog−/− tongue tissue
samples and compared the levels of expression of the putative
myogenin target genes using three different samples for each
genotype (Table 1; Fig. 2). In all cases, the fold changes in the
expression of these genes calculated using qRT-PCR confirmed
the results of the microarray experiments. Moreover, we
routinely found that the fold changes obtained using qRT-
PCR were substantially larger than those obtained in the
microarray analysis (Table 1).
We selected several strongly downregulated genes to
determine whether they were direct targets of myogenin.
Genes encoding structural and enzymatic components of
skeletal muscle whose expression was strongly dependent on
the presence of myogenin were obvious candidates for target
genes. Expression of the representative skeletal muscle struc-
tural proteins, Lmod2, Ldb3, andMyoz1 decreased significantly
inmyog−/− tongue muscle (Table 1; Fig. 2). Lmod2 is the cardiac
isoform of Leiomodin and is expressed in both heart and skeletal
muscle during embryonic and adult life (Conley et al., 2001).
Leiomodins are a family of proteins highly related to the Z-disk-
associated Tropomodulin family of actin filament end-capping
proteins (Conley et al., 2001; Fischer and Fowler, 2003). Ldb3,
also called Cypher or Zasp, contains an N-terminal PDZ domain
and three C-terminal LIM domains. Ldb3 is important for
maintaining Z-disk stability by binding to Actinin α2 in its PDZ
domain (Faulkner et al., 1999; Zhou et al., 1999; KlaavuniemiFig. 2. Expression of genes encoding structural, enzymatic, and secreted factors is do
The results of qRT-PCR analysis using RNA extracted from E15.5 tongue muscle and
changes in gene expression for myog+/+ and myog−/− samples are described in the Ma
for Rpl7. Blue bars are myog+/+ samples in which the average value of three sampl
samples in which the average value of three samples is normalized relative to the myo
are given in Table 1.and Ylanne, 2006). Myoz1, also called Fatz-1 or calsarcin-1, is a
sarcomeric protein implicated in the assembly and stabilization
of Z-disks (Takada et al., 2001).
Three other genes downregulated in myog−/− tongue muscle
had notable features that were suggestive of direct myogenin
gene targets. Fgfrl1, which had a 7.7-fold change in expression
(Table 1), is highly expressed in embryonic tongue and
diaphragm muscle but only weakly expressed in embryonic
limb muscle (Trueb and Taeschler, 2006). Tongue and
diaphragm muscle are the muscle tissues most affected by the
absence of myogenin inmyog−/−mice (Hasty et al., 1993; Venuti
et al., 1995). Ampd1 showed a 30-fold change in expression
(Table 1). A previous study identified two distinct regions of the
Ampd1 gene promoter required for expression in myocytes,
although it did not determine whether E-box-binding site were
contained within these regions (Morisaki and Holmes, 1993).
Finally, the transcript encoded by RIKEN1100001E04 showed
one of the greatest changes in expression in both microarray and
qRT-PCR analyses (Table 1). The NCBI-specified hypothetical
protein for RIKEN1100001E04 has a RhoGAP motif, which is a
motif contained in GTPase activator proteins that act on Rho/
Rac/Cdc42-like small GTPases (Zhang et al., 1997).
To confirm that the downregulated genes are in fact expressed
in the same myofibers as those expressing myogenin, we
performed immunocytochemistry with anti-myogenin M-225
antibody following in situ hybridization with Ampd1, Lmod2,
Fgfrl1, and RIKEN1100001E04 antisense probes (Fig. 3).
Because myogenin protein was localized to the nuclei in tongue
fibers and the transcripts of the abovementioned genes were
localized in the cytoplasm of these fibers, we could readily detect
the expression of both myogenin protein and gene transcripts. In
all cases, myogenin protein was expressed in the same fibers as
were the genes whose expression was downregulated in the
absence of myogenin (Fig. 3).
Many of the myogenin-dependent genes that we identified
are expressed not only in tongue muscle but also in other skeletal
muscle in embryos and in cells other than skeletal muscle cells. Ifwnregulated in E15.5 tongue muscle samples obtained from myog−/− embryos.
the primer pairs described in Table S3 are shown. Calculations of the relative fold
terials and methods section. The data are normalized relative to the fold changes
es is normalized relative to 1 as indicated on the Y axis. Red bars are myog−/−
g+/+ samples. Error bars are standard deviations from the mean. Full gene names
Fig. 3. Myogenin-downregulated genes are expressed in the same tongue muscle fibers as myogenin protein. Digoxigenin-labeled probes for Ampd1, Lmod2, Fgfrl1,
and RIKEN1100001E04 were hybridized in situ to E15.5 wild-type tongue sections (purple, cytoplasmic) followed by immunocytochemical staining with the anti-
myogenin antibody M-225 (brown, nuclear). A magnified portion of each field is shown in the lower left corner of each image. The regions selected for magnification
are indicated by dashed boxes.
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should be downregulated in tongue and non-tongue skeletal
muscle cells of myog−/− embryos. Moreover, expression of
myogenin target genes in non-skeletal muscle cells should be
unaffected by myogenin's absence. We therefore determined the
spatial expression patterns of Ampd1, Lmod2, Fgfrl1, Myoz1,
Ldb3, and RIKEN1100001E04 inmyog+/+ andmyog−/− embryos
on E15.5 using sectioned in situ hybridization. In each case, we
observed decreased expression of these genes in myog−/−
tongues compared with that in myog+/+ tongues; representative
examples using antisense probes for Ampd1,Myoz1, Lmod2 and
myog (serving as a control) are shown in Fig. 4A. Sense probes
did not show any significant labeling with comparable tongue
tissue samples (data not shown). Some of these genes are also
expressed in wild-type embryonic limb muscle and in cardiac
muscle where myog is never expressed. In myog−/− embryos,
expression of Fgfrl1, Myoz1, and Ldb3 was significantly
downregulated in hindlimb muscle but was not downregulated
in cardiac muscle (Fig. 4B). These results imply that separate
regulatory mechanisms independent of myogenin operate in
cardiac muscle to control the expression of Fgfrl1, Myoz1, and
Ldb3.
Conserved E-box elements within the regulatory regions of
myogenin-dependent genes
To find potential binding sites for myogenin and MyoD
within regulatory regions of putative target genes, we searched
for the presence of phylogenetically conserved noncodingsequences containing bHLH protein-binding sites (E-boxes)
for 10 myogenin-downregulated genes in the NCBI Mouse
Genome Resource website. These genes were chosen because
they were strongly downregulated in myog−/− skeletal muscle,
making them likely target genes for myogenin. Prior information
on regulatory sequences for these ten genes was limited only to
the proximal upstream region of Ampd1 (Morisaki and Holmes,
1993). Regulatory regions in the nine other candidate genes have
not been characterized. We focused on 10-kb regions encom-
passing DNA sequences upstream and downstream of the
transcriptional initiation sites of the candidate genes. To perform
this analysis, we used the computational tool regulatory VISTA
(rVISTA) to identify clusters of myogenin/MyoD, E-protein and
Mef2 consensus binding sites that were conserved between the
mouse and human genomes (Dubchak and Ryaboy, 2006). For
example, applying these criteria, rVISTA identified putative
myogenin/MyoD-binding sites in conserved noncoding
sequences in base pairs −1 to −356 upstream of Casq2, base
pairs −1 to −596 upstream of Lmod2, and base pairs −676 to
−1417 upstream of Ldb3 (Fig. 5; Fig. S1). The DNA sequences
containing E-box and Mef2-binding sites for these genes are
conserved between mouse and human genomes (Fig. 5). The
rVISTA analysis identified putative myogenin/MyoD-binding
sites upstream of the transcriptional initiation sites for Myoz1,
Csrp3, Ttn, Lmod2, Ldb3, Fgfrl1, Fgf6, Casq2, Ampd1, and
RIKEN1100001E04. In addition, the rVISTA analysis identified
potential myogenin/MyoD-binding sites within the first intron of
Ldb3 and RIKEN1100001E04. In a few instances, we observed
more than one myogenin/MyoD-binding site clustered within a
657J.K. Davie et al. / Developmental Biology 311 (2007) 650–664conserved region, suggesting the possibility of multiple bHLH
factor binding sites within one region (Fig. S1).
In vivo binding of myogenin and MyoD to conserved
regulatory regions
We used ChIP assays to determine whether myogenin bound
to E-box elements within the potential regulatory regions of 9
genes whose expression was downregulated in the absence ofFig. 4. Expression of myogenin-dependent genes in E15.5 tongue, limb, and heart m
Expression of myog, Ampd1, Myoz1, and Lmod2 is downregulated in myog−/− tong
myog−/− heart muscle, whereas their expression is downregulated in myog−/− inter
sections from the trunk areas of E15.5 myog+/+ (+/+) and myog−/− (−/−) embryos. Th
right dashed boxes are heart muscle and higher magnifications of these sections are s
higher magnifications of these sections are shown in the right-most panels.myogenin in vivo (Fig. 6A). We prepared chromatin extracts
from cells of E15.5 tongue tissue and cross-linked and
immunoprecipitated chromatin with anti-myogenin antibody
M-225. We designed primer sets to amplify the conserved
binding sites identified by rVISTA. In cases where we found
more than one conserved region at a gene locus, we generated
additional primer sets corresponding to the multiple potential
E-box sites. In these experiments, an upstream regulatory region
frommef2c known to have an E-box that binds to both myogeninuscle using in situ hybridization analysis shows skeletal muscle specificity. (A)
ue muscle. (B) Fgfrl1, Myoz1, and Ldb3 are expressed at wild-type levels in
costal muscle (ICM). The left-most panels show low-magnification images of
e sections selected for magnification are indicated by dashed boxes. The upper
hown the middle panels. The lower left dashed boxes are intercostal muscle and
Fig. 4 (continued).
658 J.K. Davie et al. / Developmental Biology 311 (2007) 650–664andMyoD served as a positive control (Wang et al., 2001), and a
region from the ubiquitously expressed gene Rpl7 encoding
ribosomal protein 7 served as a negative control. We considered
enrichment of chromatin-bound myogenin of fivefold or greater
with respect to the negative control as evidence of meaningful
myogenin binding.
The ChIP assay results showed that myogenin binding was
associated with regulatory regions of 8 of the 10 genes that we
analyzed (Fig. 6A). Myogenin did not bind at upstream regions
from Myoz1 and Crsp3 and first intron regions from Ldb3 and
RIKEN1100001E04 (Fig. 6A). In some genes, myogenin wasbound to an E-box element within one conserved region but not
another. For example, myogenin bound efficiently to the Ldb3
upstream conserved region but not to the Ldb3 conserved region
within the first intron (Fig. 6B). The ChIP analysis provided
direct evidence that Ampd1, Casq2, Ttn, Fgf6, Fgfrl1, Ldb3,
Lmod2, and RIKEN1100001E04 are all direct target genes of
myogenin.
The identification of conserved regulatory regions with
myogenin-binding sites also provided the opportunity to
determine whether MyoD played a role in regulating the
expression of myogenin-dependent genes within these regions.
Fig. 5. Myogenin-dependent genes have conserved E-box- and Mef2-binding site motifs in their putative regulatory regions. Examples of rVISTA plots for Casq2,
Lmod2, and Ldb3 are shown. We identified conserved noncoding sequences and consensus binding sites using the VISTA genome browser and rVISTA, respectively.
Phylogenetically conserved noncoding sequences in mouse and human genomes are depicted as pink regions, conserved untranslated regions are depicted as blue
regions, and conserved coding regions are depicted as purple regions. The green vertical lines indicate conserved Mef2 (MADS-Box)-binding sites, and the vertical
pink lines indicate the myogenin/MyoD E-Box)-binding sites. The gene orientation is indicated by thick arrowed lines. The regions containing clusters of conserved
binding sites are positioned immediately upstream of the transcriptional start site for Casq2, Lmod2, and Ldb3 and indicated by brackets. The partial sequences of the
bracketed regions are shown below the rVISTA plots. The Mef2 MADS-box-binding sites are boxed in green and the myogenin/MyoD E-box-binding sites are boxed
in pink. The numbers represent the base pair coordinates with −1 assigned the base pair immediately adjacent to the translational start A(TG) for each gene.
659J.K. Davie et al. / Developmental Biology 311 (2007) 650–664As hypothesized by Cao et al. (2006), MyoD may function in
remodeling chromatin rather than functioning directly as a
transcriptional activator. Accordingly, we repeated the ChIP
experiments with antibodies against both myogenin and MyoD
and E15.5 tongue muscle extracts. Control experiments showed
that myogenin and MyoD were bound to bHLH E-box
elements within the regulatory site in mef2c (Fig. 6A). In
contrast, the upstream bHLH E-box elements within the
conserved regions in Ampd1, Casq2, Fgf6, Fgfrl1, Ldb3, and
Lmod2 were ineffective binding sites for MyoD. Of the 10
myogenin target genes analyzed using ChIP, only conserved
regions in RIKEN1100001E04 and Ttn had significant MyoDbinding (Fig. 6A). These results support the hypothesis that
myogenin is able to activate transcription from E-boxes within
the putative regulatory regions of these target genes without
simultaneous input from MyoD.
Transcriptional activity of putative regulatory regions of
myogenin target genes
The conserved regulatory regions associated with the myo-
genin target genes are potentially useful for determining the
basis of myogenin's transcriptional selectivity. We sought to
determine whether the putative regulatory sites that bound to
Fig. 6. ChIP analysis of myogenin and Myod using chromatin extracted from E15.5 tongue tissue samples. (A) Myogenin binds to conserved regions containing E-
boxes. The ChIP results are graphed as fold enrichment as indicated on the Yaxis for the antibody samples versus the no-antibody control samples normalized to Rpl7.
The data represent the mean of three independent experiments, with each PCR performed in duplicate. The base pair positions shown for each gene name represent the
primer sites in reference to the translational A(TG) start sites. Blue bars represent the ChIP results for myogenin, and red bars represent the ChIP results for MyoD.
Error bars are standard deviations from the mean. (B) ChIP analysis of conserved regulatory regions in Casq2, Ldb3, and mef2. The left panel shows representative
agarose gel profiles for the regulatory regions of the indicated genes using the M-225 anti-myogenin antibody, and the right panel shows fold enrichment for the
regulatory regions calculated from qPCR values using the same DNA samples.
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reporter gene in transient transfection assays. Regulatory regions
of Ampd1, Ldb3, Lmod2, and Casq2 were cloned into pGL3
lacking a eukaryotic promoter.
We first introduced these constructs into C2C12 myoblasts
under either proliferating or differentiating conditions. In pro-
liferating C2C12 myoblasts, myoD is expressed at high levels
but myog is not expressed (Cornelison and Wold, 1997; Shen
et al., 2003); after differentiation for 48 h, both myoD and myog
are expressed at high levels (Cornelison and Wold, 1997; Shen
et al., 2003). In proliferating cells, we detected reporter gene
expression using regulatory regions of Ampd1, Casq2, and
Lmod2, although the activity of these regulatory regions was
only modestly enhanced over that of empty vector controls
(Fig. 7A). We found somewhat higher reporter gene activity
using the regulatory region of Ldb3. In contrast, after
differentiation for 48 h, the transcriptional activity of all theregulatory regions was greatly enhanced; reporter gene expres-
sion was 3-fold to 31-fold higher in differentiating cells than in
proliferating cells for the regulatory regions that we tested
(Fig. 7A). Because MyoD is present in both proliferating and
differentiating C2C12 cells, the results suggested that myogenin
was specifically required for the observed enhancement of
transcriptional activity.
In another set of experiments, we used NIH-3T3 fibroblasts,
which do not express myoD or myogenin, in transactivation
assays. In these experiments, we co-transfected expression con-
structs containing eithermyoD ormyog alongwith the regulatory
region reporter gene constructs to determine whether overex-
pression ofmyoD ormyog could stimulate transcription from the
regulatory regions of genes we identified by rVISTA. Introdu-
cing the regulatory region reporter gene constructs alone into
NIH-3T3 cells resulted in low but detectable reporter gene
expression in all cases (Fig. 7B). When we induced co-
Fig. 7. The putative regulatory regions in the myogenin-dependent genes, Ampd1, Ldb3, Casq2, and Lmod2 are able to activate expression of the luciferase reporter
gene. The sequences of these regulatory regions are shown in Fig. S1. (A) Transient transfections of regulatory regions into proliferating and differentiating C2C12
myoblasts. Gray bars show the activity in proliferating myoblasts, and black bars show the activity in differentiating myoblasts. (B–D) Transient transfections of
regulatory regions into NIH-3T3 cells co-transfected with no expression vector or expression vectors containing either myogenin or MyoD. The data for both C2C12
and NIH-3T3 cells are expressed as a percentage of the pGL3 control vector expression levels. Gray bars show activity when the myog expression construct is co-
transfected, black bars show the activity when themyoD construct is co-transfected, and white bars show the activity when no expression construct is co-transfected. In
panels C and D, activities of the regulatory regions from Lmod2 and Ampd1 are shown. In panel C, the dashed bar shows the activity when the math5 construct is co-
transfected. In panel D, ΔE-box refers to the regulatory regions from Lmod2 and Ampd1 in which the myogenin/MyoD E-box-binding sites were deleted. Error bars
are standard deviations from the mean.
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reporter gene constructs, the transcriptional activity was stimu-
lated from 4-fold to 56-fold depending on the regulatory region
(Fig. 7B). However, both MyoD and myogenin were able to
stimulate transcription in these transactivation experiments; in
fact, MyoD was generally more effective than was myogenin.
Transfections using concentrations ofmyoD ormyog expression
constructs ranging from 0.05 μg to 1.0 μg showed that MyoD
was more effective at stimulating reporter gene transcription at
all concentrations (data not shown). Furthermore, when both
myoD and myog constructs were transfected together, we
observed reporter gene activity that was approximately the
average value of the two constructs transfected separately (data
not shown). The results indicated that the transcriptional
selectivity that is observed in embryonic tongue muscle is not
recapitulated in transiently transfected NIH-3T3 fibroblasts.
The consensus E-box elements in the regulatory regions
might be expected to bind to non-myogenic bHLH transcription
factors and activate transcription from these E-box sites as
effectively as MyoD or myogenin. To determine whether bHLH
factors unrelated to MyoD and myogenin could activate
transcription, we used a distantly related bHLH transcription
factor, Math5 (Mu et al., 2005); a math5 expression constructwas co-transfected with the regulatory regions from Lmod2 and
Ampd1. Co-expressing math5 with either Lmod2 or Ampd1
regulatory region reporter gene constructs did not result in
significant transcriptional activation above the empty vector
control, although co-expression with either myoD or myog
expression constructs stimulated transcription as expected
(Fig. 7C). These results indicated that the regulatory regions
from Lmod2 and Ampd21 were able to selectively respond to
myogenic bHLH regulatory factors.
To determine whether the E-box elements in the Lmod2 or
Ampd1 regulatory regions were required for MyoD-mediated
or myogenin-mediated activation, we generated constructs with
deleted E-box elements; in Lmod2 and Ampd1, a single E-box
element was deleted (see Fig. S1 for E-box sequences). The
deleted E-box reporter gene constructs responded only weakly
when co-expressed with myoD or myog expression constructs,
although reporter gene activity was not reduced to the back-
ground levels of the empty vector control (Fig. 7D). Residual
activity might be explained by the presence of Mef2 sites, which
are known to bind Mef2 factors in physical association with
MyoD andmyogenin (Berkes and Tapscott, 2005). These results
demonstrate that the E-box elements within the Lmod2 and
Ampd1 regulatory regions are the major cis-regulatory elements
662 J.K. Davie et al. / Developmental Biology 311 (2007) 650–664required for MyoD- and myogenin-mediated transcriptional
activation.
Discussion
Our results identify new target genes for myogenin and
demonstrate that in myog−/− embryonic tongue muscle, the
presence of normal levels of MyoD cannot compensate for the
absence of myogenin in regulating the expression of these target
genes. Moreover, binding sites within the upstream regulatory
regions of these target genes have myogenin but not MyoD
bound to them in vivo. Our transient transfection results with
NIH-3T3 cells suggest that the DNA sequences within the reg-
ulatory regions of the myogenin target genes cannot be solely
responsible for the transcriptional selectivity that we observe
in vivo.
The gene expression profiling and ChIP experiments we
performed are the first to use embryonic skeletal muscle to
identify potential target genes for myogenin. Our experiments
used skeletal muscle extracted from myog+/+ and myog−/−
embryos. This genetically based approach necessarily identifies
genes whose expression strictly depends on the presence of
myogenin and should thus identify genes whose expression is
directly regulated by myogenin as well as genes whose ex-
pression is regulated by indirect mechanisms that require the
presence of myogenin. The myogenin-dependent genes that
we identified are likely to be bona fide targets of myogenin
as evidenced by significant decreases in their expression in
myog−/− tongue muscle, strong correlations between gene
function and the myog−/− phenotype, and in vivo binding of
myogenin to sites within putative regulatory regions. The target
genes represent a wide variety of genes expressed in skeletal
muscle with diverse functions and transcriptional regulatory
features. They should prove useful in ongoing investigations of
the mechanisms by which myogenin exerts its specialized
functions as a myogenic regulatory factor.
Recently, several groups have identified potential MyoD and
myogenin target genes in cultured myoblasts using gene
profiling and ChIP-on-chip approaches (Blais et al., 2005,
De la Serna et al., 2005; Ishibashi et al., 2005; Cao et al., 2006).
Unexpectedly, the myogenin-dependent genes identified in our
gene expression profiling analysis of E15.5 embryonic tongue
muscle do not significantly overlap with the genes identified in
cultured myoblasts (Table S1) (Blais et al., 2005; De la Serna
et al., 2005; Ishibashi et al., 2005; Cao et al., 2006). Moreover,
there is little concordance among the cell culture studies on the
target genes that were identified. Using C2C12 myoblasts
sampled at different stages of myogenesis, Cao et al. (2006)
reported a large overlap of target genes between MyoD and
myogenin. In contrast, Blais et al. (2005), also using
differentiating C2C12 myoblasts, did not find substantial
overlap of gene targets among MyoD, myogenin, and Mef2.
In our analysis, we specifically selected genes whose expression
required the presence of myogenin, irrespective of the presence
of MyoD. Furthermore, our ChIP analysis readily detected
myogenin binding within the putative regulatory regions of
some of these genes but detected MyoD binding onlyinfrequently within these same regulatory regions. These results
suggest that the myogenin-dependent genes identified in our
analysis are distinct from those identified previously in cultured
myoblasts and may therefore be subject to different modes of
regulation.
Interestingly, the gene set of 140 downregulated genes that
we identified is largely overlapped with that identified in a
microarray analysis by Kuninger et al. (2004), who used
insulin-like growth factor (IGF)-I to induce myogenesis in
C2C12 cells. In particular, Kuninger and colleagues found that
expression of many of the genes encoding structural and enzy-
matic components of muscle that we identified as myogenin-
dependent genes was upregulated upon IGF-I induction of
myogenesis. These similarities suggest that in most cases, IGF-I
signaling is mediated through activation of myog and that the
subsequent expression of genes is transcriptionally regulated
by myogenin. Indeed, the skeletal muscle phenotype of igf1-
knockout mice is very similar to that of myog-knockout mice
(Benito et al., 1996).
The myogenin-dependent genes that we identified are only a
subset of genes expressed in skeletal muscle; the expression of
many genes encoding other structural and enzymatic compo-
nents of skeletal muscle is not significantly downregulated in
myog-null tongue muscle. The expression of these genes may
not require the action of any of the myogenic regulatory factors,
including myogenin. Alternatively, MyoD or Myf5, which are
both present in myog−/− tongue muscle, may compensate for
loss of myogenin. Our results show that myogenin is strictly
required in vivo for the normal expression of one set of genes;
without the expression of this gene set, myocyte differentiation
and myofiber formation are severely compromised. Elucidating
the mechanisms that distinguish myogenin-dependent genes
from myogenin-independent genes will add substantially to a
more precise understanding of gene regulation in skeletal muscle
development.
At E15.5, myogenesis in the embryonic tongue is hetero-
geneous; committed myoblasts are in the process of forming
myocytes and some of these myocytes are beginning to fuse to
form myofibers (Yamane, 2005). Unlike the case in which
C2C12 myoblasts are induced to differentiate into myotubes,
myogenesis in embryonic tongue tissue is not synchronous.
Therefore, it is difficult to group the myogenin-dependent genes
that we identified into early and late expressing genes. In fact, the
myogenin-dependent genes identified in our analysis apparently
are expressed at various stages of myogenesis. For example,
Fgf6 and Fgfrl1 are expressed throughout myogenesis (Trueb
et al., 2003; Armand et al., 2006), whereas genes encoding
sarcomeric Z-disk components like Myoz1 and Myoz2 are
expressed at late stages of myogenesis (Takada et al., 2001).
Cao et al. (2006) have presented evidence suggesting that
myogenin does not bind efficiently to target genes without
MyoD. Given the heterogeneity of expression of myogenin-
dependent genes in tongue muscle, one would expect to find
MyoD and myogenin bound to sites within the same regulatory
regions using ChIP analysis. However, our results indicate that
this occurs only infrequently. Because myogenin is thought to be
unable to efficiently bind to its target site without MyoD-
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Tapscott, 2005; Cao et al., 2006), our results suggest that
MyoD acts at an earlier embryonic stage in tongue muscle than
E15.5. Of course, some of the myogenin-dependent genes that
we have identified may never require MyoD for their expres-
sion in skeletal muscle, and other factors may be used for chro-
matin remodeling and myogenin's access to regulatory DNA
sequences.
Our transient transfection experiments made use of the
putative regulatory regions in myogenin-dependent genes to
determine whether exogenously introduced DNA templates
would behave in a manner similar to that observed in vivo. That
is, would the intracellular environment in cultured C2C12 myo-
blasts or NIH-3T3 fibroblasts provide a means for distinguishing
between MyoD and myogenin? Our tentative hypothesis was
that if the DNA sequences within the regulatory regions in these
genes were responsible for selective binding of myogenin rather
thanMyoD, then the transient transfection analysis would reflect
that selectivity. We would therefore expect MyoD to be in-
capable of binding and activating transcription but expect myo-
genin to perform these functions. Because myog is expressed at
high levels in differentiating myoblasts but is not expressed in
proliferating myoblasts, our results imply that myogenin is
responsible for the enhanced activity of myogenin-dependent
genes. However, because myoD is also expressed in differentiat-
ing myoblasts, we are not certain whether the regulatory regions
are responding only to myogenin and not to MyoD. In fact, in
NIH-3T3 cells, in which myog and myoD were overexpressed,
we found no evidence of sequence selectivity for myogenin. Our
results suggest that the cellular environment is a crucial factor in
determining myogenin's target gene selectivity. This environ-
ment could reflect a muscle cell-specific chromatin organization,
in which myogenic cells use factors like MyoD to remodel
chromatin. Alternatively, transcriptional co-factors may be
essential inmyogenesis to promotemyogenin's selective activity
after it binds to its target site.
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